Cancer

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis

VANCOUVER, British Columbia, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:…

11 months ago

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is…

11 months ago

MMI and ab medica Partner to Expand Access to Symani® Surgical System

Leading distributor of surgical robotics to elevate MMI’s presence in ItalyJACKSONVILLE, Fla.--(BUSINESS WIRE)--MMI, (Medical Microinstruments, Inc.), a robotics company dedicated…

11 months ago

Beauty-Stem Biomedical Teams Up With S.Y. Dao Cancer Prevention Foundation for Charitable Book Lecture on CD34 Stem Cells and Immunology

Pioneering Collaboration Unveils Charitable Lecture on Cutting-Edge Cancer PreventionLOS ANGELES, CA / ACCESSWIRE / January 10, 2024 / In a…

11 months ago

SOPHiA GENETICS Highlights Near-Term Growth Strategy at 42nd Annual J.P. Morgan Healthcare Conference

Strong SOPHiA DDM™ adoption and analysis volume contributes to continued revenue growth Liquid biopsy and HRD on SOPHiA DDM™ Platform…

11 months ago

Gilead Pays Tribute to Patient Advocacy Work: Cara’s Story

NORTHAMPTON, MA / ACCESSWIRE / January 10, 2024 / Gilead Sciences:When employees at Gilead's recently opened New Jersey office need…

11 months ago

Sona Nanotech Announces Director Retirement

Halifax, Nova Scotia--(Newsfile Corp. - January 10, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…

11 months ago

Parexel and Japanese Foundation for Cancer Research Announce Strategic Alliance

Collaboration streamlines patient access to oncology clinical trials; further expands Parexel's Site Alliance Network across Asia/PacificDURHAM, N.C. and TOKYO, Jan. 10,…

11 months ago

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and…

11 months ago